Whitepaper: Enhancing Graft Survival and Patient Outcomes: Insights from Leading Experts on Subclinical Rejection

Graft survival continues to be a critical topic in kidney transplant cases. Studies indicate that subclinical rejection occurs in roughly a quarter of all seemingly stable kidney transplant cases, and within the first 2 years, around 35% of patients experience silent rejection. Some of these cases are borderline, calling for possible clinical action. However, unless centers are completing regular surveillance biopsies—and most are not for sound practical reasons—other methods are required to assess allograft health and enhance graft survival and patient outcomes.

Dr. John Friedewald, Dr. Michael Marvin, and Dr. Namita Singh are leaders in the transplant health space. They presented their views on dealing with subclinical rejection in webinars hosted by Eurofins Transplant Genomics. This whitepaper summarizes these expert opinions and presents actionable insights to help clinicians improve patient outcomes and graft survival rates.

Want to learn more? Fill out the form and read the whitepaper for an in-depth study.